Fangdie Ye
Overview
Explore the profile of Fangdie Ye including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang J, Yu Z, Chen Z, Ye F, Sun Z
Rev Med Virol
. 2025 Jan;
35(1):e70010.
PMID: 39804234
Arboviruses currently are regarded as a major worldwide public health concern. The clinical outcomes associated with this group of viruses may vary from asymptomatic infections to severe forms of haemorrhagic...
2.
Chen Z, Zhang T, Li W, Hu J, Ou Y, Ye F, et al.
Apoptosis
. 2024 Dec;
30(1-2):282-296.
PMID: 39633115
Background: Due to the clinical characteristic of frequent recurrence in urothelial bladder cancer (UBC), patients face significant health impacts and economic burdens. Therefore, understanding the molecular mechanisms involved in UBC...
3.
Chen Z, Hu J, Ou Y, Ye F, Li W, Liu S, et al.
Front Immunol
. 2024 Sep;
15:1427124.
PMID: 39238647
Background: Ferroptosis, as a novel form of programmed cell death, plays a crucial role in the occurrence and development of bladder cancer (BCa). However, the regulatory mechanisms of ferroptosis in...
4.
Li W, Ou Y, Ye F, Cheng Z, Chen Z, Zhou Q, et al.
Cell Death Discov
. 2024 Sep;
10(1):391.
PMID: 39223162
Bladder cancer (BC) represents a prevalent and formidable malignancy necessitating innovative diagnostic and therapeutic strategies. Circular RNAs (circRNAs) have emerged as crucial regulators in cancer biology. In this study, we...
5.
Chen Z, Ou Y, Ye F, Li W, Jiang H, Liu S
J Cancer Res Clin Oncol
. 2024 May;
150(5):264.
PMID: 38767747
Background: Bladder cancer (BCa) is among the most prevalent malignant tumors affecting the urinary system. Due to its highly recurrent nature, standard treatments such as surgery often fail to significantly...
6.
Huang H, Li Q, Tu X, Yu D, Zhou Y, Ma L, et al.
Cell Oncol (Dordr)
. 2024 Mar;
47(4):1375-1389.
PMID: 38520647
Background: Recent research underscores the pivotal role of immune checkpoints as biomarkers in colorectal cancer (CRC) therapy, highlighting the dynamics of resistance and response to immune checkpoint inhibitors. The impact...
7.
Fan L, Wang J, Zhang Z, Zuo Z, Liu Y, Ye F, et al.
Funct Integr Genomics
. 2024 Mar;
24(2):56.
PMID: 38472459
Bladder cancer is a malignancy characterized by significant heterogeneity. RNA methylation has received an increasing amount of attention in recent years. RNA data were collected from the GEO database, and...
8.
Jiang S, Yang X, Lin Y, Liu Y, Tran L, Zhang J, et al.
J Gene Med
. 2024 Jan;
26(1):e3651.
PMID: 38282152
Background: Bladder cancer (BLCA) is a prevalent malignancy worldwide. Anoikis remains a new form of cell death. It is necessary to explore Anoikis-related genes in the prognosis of BLCA. Methods:...
9.
Cheng Z, Ye F, Liang Y, Xu C, Zhang Z, Ou Y, et al.
Front Nutr
. 2024 Jan;
10:992608.
PMID: 38188874
Background: The influences of blood lipids and lipid-regulatory medications on the risk of bladder cancer have long been suspected, and previous findings remain controversial. We aimed to assess the causality...
10.
Yang Q, Ye F, Li L, Chu J, Tian Y, Cao J, et al.
J Biomol Struct Dyn
. 2024 Jan;
:1-18.
PMID: 38173169
Sunitinib remains the preferred systemic treatment option for specific patients with advanced RCC who are ineligible for immune therapy. However, it's essential to recognize that Sunitinib fails to elicit a...